United Therapeutics (UTHR) is a publicly traded Healthcare sector company. As of May 21, 2026, UTHR trades at $562.26 with a market cap of $24.07B and a P/E ratio of 19.26. UTHR moved -0.44% today. Year to date, UTHR is +15.16%; over the trailing twelve months it is +82.17%. Its 52-week range spans $266.98 to $609.35. Analyst consensus is strong buy with an average price target of $647.83. Rallies surfaces UTHR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
United Therapeutics slides despite same-day Wells Fargo upgrade after Q1 results digestion: United Therapeutics was upgraded to Overweight from Equal Weight with a sharply higher price target in research published today. The stock is also digesting the company’s May 6, 2026 Q1 earnings release and call, which included a near-term revenue miss alongside reiterated longer-term growth commentary.
| Metric | Value |
|---|---|
| Price | $562.26 |
| Market Cap | $24.07B |
| P/E Ratio | 19.26 |
| EPS | $29.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $609.35 |
| 52-Week Low | $266.98 |
| Volume | 42 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.17B |
| Net Income | $1.29B |
| Gross Margin | 86.58% |
13 analysts cover UTHR: 0 strong buy, 10 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $647.83.